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Knowledge of the mechanism of action of skin penetration enhancers is essential to formulators for
optimizing formulations and to maximize the eﬃcacy of enhancers. To obtain information about the
eﬀects of penetration enhancers as a fast initial screening, investigations have been performed to identify
possible correlations of the biological eﬀectiveness of penetration enhancers with their interaction with
a well-deﬁned model system consisting of skin mimic lipid bilayers, as determined by calcein release
experiments using stratum corneum lipid liposomes (SCLLs). We aimed to investigate the enhancing
eﬀects of diﬀerent concentrations of two chemical penetration enhancers, Kolliphor RH40 and
Transcutol on SCLLs. The results obtained by SCLL-based techniques were compared with conventional
ex vivo penetration studies in case of Kolliphor RH40 to evaluate the potential of SCLLs as an alternative
tool for screening various types and concentrations of penetration enhancers. As a result, calcein
leakage assay performed with SCLL was considered to be a good model for the skin penetration
enhancing eﬀect. This method could be used as a time-saving and sensitive alternative in vitro screening
technique in the early stage of the development of dermal formulations.Introduction
The skin has been recognized as a highly attractive application
site of therapeutic agents with both local and systemic eﬀects.1
However, the outermost layer of the skin, the stratum corneum
(SC) forms a barrier, which makes it hard for active pharma-
ceutical ingredients (API) to pass through this layer and exert
their pharmacological eﬀects.2 It has been shown that the
transdermal ux of API and SC lipid conformation is strongly
correlated.3 These lipids are arranged in a bilayer structure;
thus, liposomes can be suitable systems to mimic this
arrangement in vitro.2
Stratum corneum lipid liposomes (SCLLs) are composed of
a lipid mixture approximating the composition of the SC:
ceramides (40%), cholesterol (25%), cholesteryl sulfate (10%)
and free fatty acids (25%). This lipid composition is capable of
forming unilamellar bilayers at physiological pH, and they were
shown to be really stable.4,5 These systems can be applied as in
vitromodels for screening agents of pharmaceutical or cosmetic
interest, enabling the evaluation of their interactions with the
permeability barrier.5 Also, by changing the lipid composition
of SCLLs, diﬀerent pathological conditions can be modelled,
e.g. the accumulation of cholesterol sulfate and decreased
cholesterol levels are specic for ichthyosis patients.6
To overcome the barrier function of the SC, chemical pene-
tration enhancers (CPEs) are conventional and eﬀectiveRegulatory Aﬀairs, University of Szeged,
harm.u-szeged.hu; Tel: +36-62-545-573
69approaches as they reduce skin barrier resistance and thus
promote the penetration of drugs.2,6 The mechanism of action
of CPEs is thought to be by disrupting the packing of skin lipids
and altering the barrier of the SC, by changing the partitioning
behaviour of the drug at the SC-viable epidermis interface or by
aﬀecting the thermodynamic activity of the drug.7,8 The evalu-
ation of the exact mechanism of action is crucial in the devel-
opment of transdermal and dermal formulations. Conventional
methods to investigate the eﬀects of CPEs are based on the
determination of the cumulative amount of skin permeation,
ux, and permeability coeﬃcient of drugs in the presence and
absence of CPEs by pre-treatment and partitioning studies,
spectroscopic investigations and thermal analysis.8 However,
these approaches are usually time-consuming, complicated,
and usually need skin from human or animal source.2 Nowa-
days there is an increasing awareness of animal welfare issues
and there is a lack of supply of suitable human skin, which gives
rise to a need to develop eﬀective replacement approaches to
avoid the use of excised skin.8 These intentions also support the
reason for using SCLL as skin modelling systems.
There are several methods to investigate the eﬀects of CPEs
on SCLLs. Kim et al. employed SCLLs rst to investigate the
mechanism of action of CPEs using diﬀerential scanning calo-
rimetry (DSC).8,9 The incorporation of uorescent markers in
the liposomes, and the study of their release is also a well-
known technique to measure the stability of the vesicular
membrane of SCLL, and to investigate the eﬀects of CPEs on
this stability.10–12This journal is © The Royal Society of Chemistry 2018
Table 1 Particle size and PDI of SCLLs with and without calcein
Z-ave (nm) PDI
SCLL 135.23  0.06 0.220  0.02
Calcein-loaded SCLL 137.35  0.07 0.228  0.02
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View Article OnlineIn this study, we aimed to investigate the eﬀects of two
modern penetration enhancers: Kolliphor RH40 and
Transcutol.
Kolliphor RH40 (Polyoxyl 40 Hydrogenated Castor Oil USP/
NF) is a nonionic surfactant reported to shi the drug distri-
bution to the stratum corneum, but the exact mechanism was
not described yet.13,14 Generally, non-ionic surfactants have low
toxicity, however, they have also a minor enhancement eﬀect
compared to ionic types, which could be explained by the low
degree of SC structure disordering eﬀect.15 Breuer suggested two
possible mechanisms to describe how nonionic surfactants
enhance the rate of transport: (I) surfactants may penetrate into
the intercellular regions of the stratum corneum, increase
uidity and, at last, solubilise and extract lipid components; (II)
the penetration of a surfactant into the intercellular matrix
followed by interactions and binding with keratin laments
may result in a disruption within the corneocyte.16
Transcutol, a monoethyl ether of diethylene glycol, is clas-
sied into the group of alcohols and glycols, which are reported
to interact with the aqueous domain of the lipid bilayers, which
increase the solubility of drugs in the skin.1 Harrison et al. re-
ported that the penetration enhancement property of Trans-
cutol is the result of changes in solubility rather than diﬀusion
in the membrane. Another study stated that the enhancing
ability of Transcutol is attributed to its ability to pass through
the skin and get incorporated into the multiple lipid bilayers,
thereby swelling the intercellular lipids.13 These results suggest
that further mechanistic studies are required to elucidate its
exact interaction with skin components.
The present study attempts to investigate the lipid interac-
tions and enhancer eﬀects of the above-mentioned CPEs in an
isolated lipoidal system of SCLLs using uorescent dye eﬄux
and ex vivo penetration experiments. The correlation between
novel in vitro SCLL leakage results and conventional ex vivo skin
penetration results was investigated to determine the applica-
bility of SCLL liposomes as skin modelling systems.
Experimental
Materials
Ceramide (type III and VI) was kindly supplied by Evonik
Industries (Evonik Nutrition & Care GmbH, Essen, Germany).
Cholesterol and caﬀeine were purchased from Hungaropharma
Plc. (Budapest, Hungary). Cholesterol sulfate and EDTA were
obtained from Sigma-Aldrich (Saint Louis, Missouri, USA).
Palmitic acid was supplied by Mosselman s.a. (Ghlin, Belgium).
Kolliphor RH40 was obtained from BASF SE (Ludwigshafen,
Germany). Transcutol was a kind gi of Azelis Hungary Ltd.
(Budapest, Hungary). Organic solvents (chloroform and meth-
anol), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) and sodium chloride (purity $ 99.5%) were from Carl
Roth GmbH & Co. KG (Karlsruhe, Germany). HPTLC plates (20
 10 cm silica-gel 60 WRF254s) were delivered by Merck
(Darmstadt, Germany). Mobile-phase components, solvents for
lipids and o-phosphoric acid 85% were purchased from Carl
Roth GmbH (Karlsruhe, Germany) and were of HPLC or p.a.
quality. HPLC grade water was prepared from Milli-Q waterThis journal is © The Royal Society of Chemistry 2018purication system (Merck Type 1, Millipore, Milford, MA, USA)
and methanol (gradient grade, suitable for HPLC/UHPLC
measurements) was purchased from VWR Scientic (Seattle,
WA, USA).SCLL preparation
The preparation of SCLL liposomes followed the method
described by Wertz et al.5 Briey, individual lipids were dis-
solved in chloroform–methanol (2 : 1 by volume) and appro-
priate volumes were combined to obtain the corresponding
mixture (ceramides : cholesterol : palmitic acid : cholesterol
sulfate ¼ 4 : 2.5 : 2.5 : 1, weight percent). The lipid mixture was
then placed in a culture tube, and the solvent was removed with
a stream of nitrogen (Christ RVC 2-18 rotary evaporator) and
then under high vacuum at room temperature. Aqueous
dispersions of each lipid mixture were prepared by suspension
in buﬀer containing 20 mM HEPES, 120 mM NaCl, 0.8 mM
EDTA (supplemented with 70 mM calcein dye for eﬄux
measurements), to provide a nal concentration of 5 mg mL1
lipid at pH 8. The lipids were le to hydrate for 30 min with
occasional shaking. The suspensions were then sonicated in
a bath sonicator at 80 C (temperatures slightly higher than
those corresponding to the phase transition temperature for
each lipid mixture) for about 1 h until the suspensions became
clear. The preparations were then annealed at the same
temperature for 30 min. Liposomal formulations were stored at
4 C and used within 1 day.Particle size and polydispersity index of SCLL
The mean vesicle size and polydispersity indexes of liposome
suspensions were determined using Malvern Nano ZS system
(Malvern Instruments, Malvern, UK) based on dynamic light
scattering. The samples were diluted with their aqueous phase
in order to avoid multiscattering phenomena, and then they
were incubated at 25 C. Measurements were made in standard
disposable cuvettes, each of them in triplicate. The poly-
dispersity index was also calculated to evaluate the homogeneity
of the dispersion.Calcein eﬄux and lifetime-based uorescence leakage assay
Calcein leakage assay is based on the fact that the entrapped
calcein expresses only slight uorescence due to self-quenching
or co-entrapment of a quencher, but when it is released from
the liposomes and attenuates, it shows uorescence. Eﬄux E is
dened as the fraction of previously entrapped calcein that was
released within a dened time point aer exposure to the per-
meabilizer.17 The degree of calcein eﬄux from SCLLs refers to
the degree of disruption eﬀect brought about by CPEs.RSC Adv., 2018, 8, 27464–27469 | 27465
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View Article OnlineThe prompt-deconvoluted t of the decay curve aer freeing
all calcein in a vesicle dispersion provides a virtually mono-
exponential behavior with a lifetime of s ¼ 4.0 ns. The curve for
calcein-loaded vesicles in the absence of a permeabilizer results
in a biexponential behavior with a dominant BE (subscript E for
entrapped) with s ¼ 0.4 ns and a weak BF0 (subscript F for free
and 0 for ‘without permeabilizer’) with s ¼ 4.0 ns from some
remaining free dye. Generally, increasing detergent concentra-
tions lead to a growth of the long-lived component (free dye) at
the expense of the short-lived one (entrapped). This can be
quantied as the eﬄux.
Calcein eﬄux (E) was calculated according to the following
equation:18
E ¼

BF  BF0


BF  BF0 þ Qstat BE
 (1)
where B is the pre-exponential factor (proportional to the
concentrations of free and entrapped dye). BF0 corresponds to
the free dye at the beginning of the measurement (this corrects
for incomplete dye removal on the column), BF to the free dye
concentration at certain time points and BE to the entrapped
calcein concentration. Qstat is the static quenching factor, which
considers that some entrapped dye might be ‘invisible’ due to
dimerization in the ground state. We used 1.2 as Qstat based on
the literature.18
Before the uorescence measurements, vesicles were sepa-
rated from unencapsulated uorescent dye on a PD-10 de-
salting column (GE Healthcare) using HEPES buﬀer (20 mM
HEPES, 120 mM NaCl, 0.8 mM EDTA) as the mobile phase. 5 mL
aliquots of these vesicles were incubated with diﬀerent
concentrations of surfactant, at room temperature on a gently
rotating shaker and eﬄux measurements were performed aer
1, 10, 30 min, 1, 2, 3 h. The samples were placed in a Horiba
Jobin Yvon (Edison, NJ) Fluorolog 3 system equipped with
a 467 nm laser diode pulsed at 1 MHz for excitation; the decay
curve was recorded at a wavelength of 515 nm (bandwidth 2 nm)
for 25 s using time-correlated single photon counting (TCSPC).
We used HORIBA DAS6 soware to t decay curves biexpo-
nentially by deconvoluting them with the instrument response
function as measured with a scattering LUDOX solution.Ex vivo skin penetration experiments
For the penetration experiments, heat separated human
epidermis was used.19 Excised human skin was obtained from
a Caucasian female patient. All experiments were performed in
accordance with the OECD Guideline 428: Skin Absorption: In
Vitro Method (2004). Experiments were approved by the Ethical
Committee of University of Szeged (Albert Szent-Gyo¨rgyi Clin-
ical Centre, Human Investigation Review Board license number:
83/2008.). Informed consents were obtained from human
participants of this study. The separated epidermal membrane
was applied onto the surface of PBS (phosphate buﬀer solution,
pH ¼ 7.4) for at least 20 min, then set on a supporting mixed
cellulose ester membrane (Poral, Machenerey-Nagel, Du¨ren,
Germany; pore diameter 0.45 mm) and mounted in a vertical
Franz diﬀusion cell (Hanson Research, Chatsworth, CA, USA) in27466 | RSC Adv., 2018, 8, 27464–27469a six-unit assembly (eﬀective permeation area 1.676 cm2) over
24 h at 32  0.5 C. PBS pH 7.4 was used as the acceptor
medium and it was stirred at 450 rpm throughout the experi-
ment. At selected time intervals, samples of 0.8 mL were taken
from the acceptor phase by the autosampler (Hanson Research,
Chatsworth, CA, USA) and replaced with an equal volume of
fresh receiver medium.
The donor chamber was lled with 1 mL of 2 mg mL1
caﬀeine solution, providing innite dosing, with dened
amounts of CPEs in PBS. The amount of permeated drug was
measured using a high-performance liquid chromatography
(HPLC) system.
Five parallel measurements were carried out and the amount
of caﬀeine penetrating during a time period was plotted. The
results were expressed as means SD for the evaluation of drug
release kinetics.
The penetration of caﬀeine was calculated in terms of the
mean cumulative amount permeated through the membrane,
taking the diﬀusion area into account. The results were plotted
as a function of time.
HPLC analysis of caﬀeine
The HPLC analysis of caﬀeine was performed with a Shimadzu
Nexera X2 UHPLC system. The system control and data acqui-
sition were performed with Shimadzu LabSolutions soware
package. The chromatographic separation was achieved by
Phenomenex Kinetex C18 column with 2.6 mm particle size (150
 4.6 mm I.D.). The column temperature was maintained at
25 C. The separations were carried out in isocratic mode. The
mobile phase of pure HPLC grade water and methanol in the
ratio of 75 : 25 was pumped at a ow rate of 1.0 mL min1. For
the detection of caﬀeine, a PDA detector was used. The wave-
length of detection was 272 nm and the detector cell tempera-
ture was adjusted to 40 C. The sample tray holder's
temperature was 25 C, the injected volume of the samples was
5 mL. The analysis time was 7 min, the retention time of caﬀeine
was 5.1 min.
Results
SCLL characteristics: particle size and polydispersity index
The lipidmixture, representing stratum corneum lipids, formed
liposomes in the size of 135.23  0.06 nm. The polydispersity
index (PDI) was 0.220  0.02 (Table 1). The particle size of the
calcein-loaded SCLL was 137.35  0.07 nm and their poly-
dispersity index was 0.228  0.02. The electron microscopic
images revealed that most of the particles were unilamellar
(Fig. 1).
Calcein eﬄux and lifetime-based uorescence leakage assay
The eﬀect of diﬀerent concentrations of Kolliphor RH40 and
Transcutol was tested on the disruption of SCLLs applying
calcein leakage assay.
First, the correlation between the enhancer concentration
and the eﬄux was investigated for 3 hours (Fig. 2). Both Kolli-
phor RH40 and Transcutol promoted calcein eﬄux from SCLLsThis journal is © The Royal Society of Chemistry 2018
Fig. 1 Transmission electron microscope images of SCLLs (A) and
calcein-loaded SCLLs (B).
Fig. 2 Eﬄux from SCLLs induced by Kolliphor RH40 (A) and Trans-
cutol (B) as a function of incubation time. The concentrations of the
CPEs are indicated in the plot.
Fig. 3 Calcein eﬄux from SCLLs after 1 h of incubation as a function of
CPE concentration (:: Kolliphor RH40,C: Transcutol).
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View Article Onlinein a concentration dependent manner. However, from Trans-
cutol, much higher concentration was needed to achieve the
same eﬄux value. The eﬄux curve for Transcutol reaches
a plateau value aer about 1 hour, while the calcein eﬄux
caused by Kolliphor RH40 increases even aer 2 hours. ForThis journal is © The Royal Society of Chemistry 2018longer waiting times, there is only a slight further increase with
a much slower rate.
Then, we investigated the relationship between CPE
concentration and calcein eﬄux aer 1 hour. The concentration
proles of the eﬄux were diﬀerent for the two investigated
CPEs. Kolliphor RH40 showed a linear relationship between
calcein eﬄux and concentration, while in case of Transcutol
a concave downward prole was observable, which indicated
the limit level for the disruption of SCLLs (Fig. 3).
However, these results do not give detailed information
about the characteristics of vesicle disruption. The eﬄux can
result mainly from two mechanisms: (i) all-or-none, when only
some vesicles are disrupted (and releasing all entrapped dye)
while others remain undamaged or (ii) graded, when all vesicles
release a certain fraction of their content.
The uorescence lifetime measurement method published
by Patel et al.18 can distinguish between these two mechanisms
by plotting calcein eﬄux (E) versus lifetime of entrapped dye
(sE). Ideally, homogeneously graded leakage points of the above-
mentioned graph should lie on the diagonal (eﬄux E couples
directly with the entrapped calcein concentration: the more has
leaked out, the less is le behind, which correlates with sE). The
right-shi of E(sE) from the diagonal is a measure for the
heterogeneity of graded leakage. All-or-none leakage increases
E, but does not aﬀect sE since the entrapped calcein concen-
tration in the non-leaky vesicles remains 0.4 ns and the empty
vesicles do not contribute to sE at all, thus E(sE) should follow
a vertical line at sE 0.4.
Vesicles incubated with Kolliphor RH40 showed all-or-none
leakage mechanism until a certain point around 60% eﬄux,
then it became graded. The eﬄux increases with increasing
concentration of Kolliphor RH40 and with time (Fig. 4A).
Transcutol caused graded leakage of the vesicles, which is in
agreement with the previous results: calcein eﬄux is not
promoted at lower concentrations, a certain concentration of
Transcutol is needed to increase the eﬄux to a great extent
(Fig. 4B). This nding is in agreement with a previous study.1
Transcutol is reported to interact in the aqueous domain of the
lipid bilayers which increase the solubility of drugs in the skin.
According to Moghadam et al., Transcutol caused only a slightRSC Adv., 2018, 8, 27464–27469 | 27467
Fig. 4 Calcein eﬄux as a function of the entrapped ﬂuorescence lifetime on a reciprocal scale brought on by Kolliphor RH40 (A) and
Transcutol (B).
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View Article Onlinedisordering eﬀect within the SC membrane. They also proved
the superior enhancer eﬀect of Kolliphor RH40.14Eﬀect of CPEs on ex vivo penetration of caﬀeine
In this work, we selected caﬀeine as a hydrophilic model drug to
determine the penetration enhancer eﬀect of diﬀerent concen-
trations of Kolliphor RH40 on human epidermis ex vivo. Fig. 5
shows the cumulative amounts of caﬀeine penetrated through
heat separated epidermis over 24 hours.
It can be stated that the ex vivo penetration of caﬀeine was
strongly dependent on the concentration of Kolliphor RH40.
With an increasing concentration of the penetration enhancer,
the skin penetration of caﬀeine also increased. The highest
concentration of Kolliphor RH40 applied was 8.1% and it
caused 21% increase in the penetration of caﬀeine compared to
the blank caﬀeine solution aer 24 h.Fig. 5 Cumulative amount of caﬀeine penetrated through heat
separated epidermis after application of diﬀerent concentrations of
Kolliphor RH40.
27468 | RSC Adv., 2018, 8, 27464–27469Relationship between calcein leakage and ex vivo skin
penetration
Calcein leakage assay performed with SCLLs was applied as an
in vitro model to investigate the enhancing eﬀect of CPEs. We
attempted to evaluate the correlation between the in vitro SCLL-
based data and the ex vivo results gained by conventional
penetration experiments. For this reason, we evaluated the
change in the penetrated amount of caﬀeine compared to the
blank formulation and the increase in eﬄux in vitro compared
to SCLLs without enhancer aer 1 and 2 hours.
Fig. 6 shows the relationship between the increase in the
cumulative permeated amount of caﬀeine compared to blank
solution and calcein leakage from SCLLs. The correlation
coeﬃcient of this relationship was 0.915 aer 1 h and 0.954
aer 2 h. According to the results, Kolliphor RH40 aﬀected SCLL
disruption more markedly than the skin permeation of caﬀeine,
which could be the result of diﬀerent lipid-enhancer ratios in
these cases.Fig. 6 Relationship between calcein leakage and increase in the
caﬀeine permeated compared to blank formulation after 1 and 2
hours.
This journal is © The Royal Society of Chemistry 2018
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View Article OnlineConclusion
Most chemical penetration enhancers act upon the skin by
permeabilizing the lipid bilayer membranes in the stratum
corneum. The permeabilizing mechanism can be assessed by
vesicle leakage experiments that use model membranes, with
the assumption that biological activity arises from per-
meabilization of the lipid bilayer. To this end, we used a life-
time-based leakage assay with calcein-loaded vesicles to study
and compare the membrane permeabilizing properties of
diﬀerent concentrations of novel CPEs like Kolliphor RH40 and
Transcutol.
We attempted to compare the results of this in vitro high
throughput screening method with conventional ex vivo pene-
tration study results in case of Kolliphor RH40. Both the eﬄux
in vitro and caﬀeine penetration ex vivo were concentration-
dependent.
Our results suggest that SCLLs could be promising in vitro
approaches for screening the eﬀects and eﬀective concentra-
tions of chemical penetration enhancers as we found a good
correlation between SCLL-based experiments and the skin
penetration study.
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